Jiang, Shangqing Joyce
Thomas, Minta
Rosenthal, Elisabeth A.
Phipps, Amanda I.
Sakoda, Lori C.
van Duijnhoven, Franzel J. B.
Pellatt, Andrew J.
Avery, Christy L.
Berndt, Sonja I.
Bishop, D. Timothy
Castellví-Bel, Sergi
Chan, Andrew T.
Grant, Robert C.
Gignoux, Chris
Gsur, Andrea
Gunter, Marc J.
Haiman, Christopher A.
Hoffmeister, Michael
Jarvik, Gail P.
Jenkins, Mark A.
Keku, Temitope O.
Küry, Sébastien
Lee, Jeffrey K.
Marchand, Loic Le
Moreno, Victor
Newcomb, Polly A.
Newton, Christina C.
Ogino, Shuji
Palmer, Julie R.
Pearlman, Rachel
Qu, Conghui
Schoen, Robert E.
Um, Caroline Y.
Van Guelpen, Bethany
Visvanathan, Kala
Vymetalkova, Veronika
White, Emily
Woods, Michael O.
Platz, Elizabeth A.
Brenner, Hermann
Corley, Douglas A.
Vogelaar, Iris Landorp
Hsu, Li
Peters, Ulrike
Funding for this research was provided by:
National Human Genome Research Institute (U01HG008657)
National Cancer Institute (U01 CA164973, R01 CA126895, R01 CA060987, R01 CA072520, U24 CA074806, U01 CA137088)
Article History
Received: 7 May 2025
Accepted: 24 September 2025
First Online: 30 October 2025
Declarations
:
: A.C. None with the current work. For work unrelated to this manuscript, getting consulting income from Boehringer Ingelheim and Pfizer Inc.Research support from Freenome Holdings.B.V.G Lecturer honorarium from AstraZeneca AB for educational activities unrelated to this work.L.C.S Research funding from AstraZeneca paid to institution and unrelated to work.R.C.G Graduate scholarship from Pfizer. Research funding from TD Bank. Paid consulting or advisory roles for Astrazeneca, Tempus, Eisai, Incyte, Knight Therapeutics, Guardant Health, and Ipsen. U.P. was a consultant with AbbVie and her husband is holding individual stocks for the following companies: Amazon, ARM Holdings PLC, BioNTech, BYD Company Limited, Crowdstrike Holdings Inc, CureVac, Google/Alphabet, Microsoft Corp, NVIDIA Corp, Stellantis. The remaining authors declare no competing interests.